Oncology & Hematology Clinical Trial Experience
A deep bench of knowledge that pairs oncology development expertise with wide-ranging rare disease experience in the largest areas of unmet need, including new treatments in cell and gene therapies and immuno-oncology.
The tireless pursuit of novel oncology treatments
The new course of cancer therapy
Precision medicine – devising patient-specific treatments to combat diseases once considered incurable – is radically changing the way the world looks at cancer therapy. The leaders in this field are small biotech and specialty pharmaceutical companies – organizations sometimes no larger than a few people and a single molecule. Our clinical trial expertise helps you get from brilliant idea to life-changing reality.
Why choose Premier?
- More than 170 hematology and oncology clinical trials completed through every phase, including multiple rare cancer and cell and gene therapy studies
- Expertise ranging from small dose-finding studies to large multinational trials
- Every aspect, from trial design and investigators to sites and patient selection, customized for your indication – including preferential regulatory pathways and other strategies for successful early planning and engagement
Safety considerations for CAR T
Safety considerations related to CAR T-cells may impact both trial design and trial management. Consequently, anticipating, preventing and managing toxicity is a key component of clinical studies involving CAR T-cells.
Finding the fast track
Sponsors of first-in-human trials of novel oncology compounds face significant challenges. Track a hypothetical drug through its development paces, exploring the many aspects you must consider when performing early-stage oncology research.
Premier Thought Leadership
Luke Gill heads our hematology/oncology group and has more than 20 years of drug development experience behind him. Specializing in oncology, he has led numerous global CRO management teams and provided strategic assessment, management, and oversight of study enrollment and program metrics. Luke holds a master’s degree in neuro and molecular pharmacology from the University of Bristol, a bachelor’s degree in biological sciences from the University of the West of England, and an MBA specializing in strategy and international enterprise from the Open University in the U.K.